Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 2 of 2 entries
View as:
Phase: N/A
Priority: Normal
Start: 08/17/23
End: 12/31/25
Due: 12/31/26
Phase: N/A
Priority: Normal
Start: 06/30/20
End: 02/07/22
Due: 02/07/23
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCED | NCT05966493 | Amber Ophthalmics, Inc. | user2@example.com | None | 2023-08-17 | 2025-12-31 | 2026-12-31 | - | - | 2025-07-14 |
| NEXAGON for the Treatment of Corneal Persistent Epithelial Defects Following Severe Ocular Injuries | NCT04081103 | Amber Ophthalmics, Inc. | user2@example.com | None | 2020-06-30 | 2022-02-07 | 2023-02-07 | - | - | 2025-07-14 |